Abstract: Conditional knockout of ASK1 in Mi/Mϕ reduced seizure severity, neurobehavioral impairments, and histological damage, at least via inhibiting proinflammatory microglia/macrophages responses. ASK1 in microglia/macrophages is a potential therapeutic target for inflammatory responses in epilepsy.
Introduction
Epilepsy is a chronic neurological disorder affecting over 70 million people globally. Despite the availability of numerous anti-seizure medications, approximately 40% of patients remain refractory to treatment. Furthermore, epilepsy is often accompanied by significant comorbidities, including cognitive impairment, anxiety, and social dysfunction, which are poorly addressed by current therapies. Recent evidence suggests that neuroinflammation, mediated primarily by microglia and infiltrating macrophages (Mi/Mϕ), plays a critical role in the pathogenesis of epilepsy. Apoptosis signal-regulating kinase 1 (ASK1) is a known mediator of stress-induced cell death and inflammation, but its specific role in microglial polarization during epilepsy has not been fully elucidated.
Methods
The researchers employed a conditional knockout (cKO) mouse model ($ASK1^{f/f};CX3CR1^{CreER}$) to selectively delete ASK1 in Mi/Mϕ upon tamoxifen administration. Epilepsy was induced using the intrahippocampal kainic acid (KA) model, characterized by an initial status epilepticus followed by chronic spontaneous recurrent seizures. Evaluation included video monitoring for seizure activity, behavioral assays (Y-maze, Three-chamber test, Morris water maze), and molecular techniques (RT-qPCR, Western blotting, immunofluorescence) to assess inflammatory markers and signaling pathways.
Key Insights and Ideas
A central finding of this study is that ASK1 acts as a molecular switch for microglial polarization. Following KA-induced seizures, ASK1 expression significantly increases in microglia, peaking at 3 days post-insult.
The deletion of ASK1 shifts the microglial phenotype from a pro-inflammatory (M1-like) state to an anti-inflammatory (M2-like) state. Furthermore, ASK1-deficient microglia exhibited enhanced efferocytosis, characterized by increased contact with and engulfment of apoptotic neurons, thereby promoting tissue repair and reducing secondary damage. This effect is mediated through the inhibition of downstream JNK and p38 MAPK signaling pathways.
Key Results
- Seizure Mitigation: ASK1 cKO mice exhibited significantly reduced frequency and severity of both acute and chronic spontaneous recurrent seizures ($p < 0.05$).
- Neurobehavioral Recovery: The knockout successfully rescued deficits in working memory (Y-maze) and social novelty preference (Three-chamber test) observed in wild-type epileptic mice.
- Histopathological Protection: Loss of ASK1 in Mi/Mϕ led to preserved neuronal density in the hippocampal CA1 region and a marked reduction in pro-inflammatory cytokines such as TNF-α, IL-1β, and CD16.
Limitations and Future Work
While promising, the study has limitations. Seizure monitoring relied on video analysis rather than gold-standard EEG, potentially missing subclinical events. The use of the $CX3CR1$ promoter affects both resident microglia and peripheral macrophages; future work using more specific markers like $Tmem119$ is needed to isolate the contribution of each cell type. Additionally, validating these findings in other epilepsy models (e.g., pilocarpine) and investigating the impact of ASK1 on baseline synaptic activity will be crucial for therapeutic development.
Conclusion
This research positions ASK1 as a high-value target for disease-modifying therapies that could potentially stop the progression of epilepsy and its associated cognitive decline by modulating the neuroinflammatory environment.
Summary updated